Prevalence of urinary schistosomiasis in women: a systematic review and meta-analysis of recently published literature (2016–2020)

Morteza Shams1, Sasan Khazaei2, Ezatollah Ghasemi3, Naser Nazari4, Erfan Javanmardi5, Hamidreza Majidiani6, Saeed Bahadory2, Davood Anvari7,8, Mohammad Fatollahzadeh9, Taher Nemati9 and Ali Asghari10*

Abstract

Background: Urinary schistosomiasis is a serious threat in endemic territories of Africa and the Middle East. The status of female urinary schistosomiasis (FUS) in published literature between 2016 and 2020 was investigated.

Methods: A systematic search in PubMed, Scopus, Google Scholar, and Web of Science, based on the 'Preferred Reporting Items for Systematic Reviews and Meta-analyses' checklist, and a meta-analysis using random-effects model to calculate the weighted estimates and 95% confidence intervals (95% CIs) were done.

Results: Totally, 113 datasets reported data on 40,531 women from 21 African countries, showing a pooled prevalence of 17.5% (95% CI: 14.8–20.5%). Most studies (73) were performed in Nigeria, while highest prevalence was detected in Mozambique 58% (95% CI: 56.9–59.1%) (one study). By sample type and symptoms, vaginal lavage [25.0% (95% CI: 11.4–46.1%)] and hematuria 19.4% (95% CI: 12.2–29.4%) showed higher FUS frequency. Studies using direct microscopy diagnosed a 17.1% (95% CI: 14.5–20.1%) prevalence rate, higher than PCR-based studies 15.3% (95% CI: 6.1–33.2%). Except for sample type, all other variables had significant association with the overall prevalence of FUS.

Conclusions: More studies are needed to evaluate the true epidemiology of FUS throughout endemic regions.

Keywords: Epidemiology, Urinary schistosomiasis, Women, Meta-analysis

Background

Schistosomiasis, due to trematodes of the genus Schistosoma (blood flukes), is a snail-transmitted helminthiasis and the third most degenerative tropical disease with substantial morbidity/mortality rates, particularly in low- and middle-income countries [1]. With about 800 million at-risk individuals, schistosomiasis afflicts over 250 million people in tropical and subtropical territories and renders approximately 70 million disability-adjusted life years [1–3]. In endemic areas such as sub-Saharan Africa morbidity is higher among school-aged children (60–80%) than adults (20–40%), with a mortality rate of 280,000 people [4]. Six species out of 24 recognized schistosomes result in disease in humans, comprising Schistosoma haematobium (S. haematobium) the causative agent of urogenital schistosomiasis (UGS), S. japonicum, S. mansoni, S. intercalatum, S. mekongi and S. guineensis as agents of hepato-intestinal disease [5]. In a public health perspective, Africa and the Mideast (S. mansoni and S. haematobium), Southeast Asia (S. japonicum) and...
Latin America (S. mansoni) are considered as the most distinguished geographical hotspots for schistosomiasis [6]. Adult paired worms would stay alive in host’s blood stream for about 3–10 years and produce numerous spiny eggs, rendering chronicity and pathologic outcomes of the infection [7–9].

The putative signs and symptoms of UGS were initially ascribed about 1900 Before the Common Era (BCE), when hematuria was a common finding in Egyptian males, referred to as “menstruation” [10]. Infected planorbid snails, Bulinus spp., are intermediate hosts releasing motile furcocercous cercariae in surrounding water supplies. Following skin cercarial invasion and migration thorough lungs and liver, S. haematobium worms would finally lodge in the genitourinary venous complex, in particular bladder veins, where they mature and copulate therein [11]. Although harsh disease outcomes primarily arise from the T-cell mediated, granulomatous immune responses against tissue-deposited spiny eggs of schistosomes. Such lesions would represent manifestations comprising hematuria, dysuria, itching, pelvic pain, as well as the life-threatening squamous cell carcinoma of the urinary bladder [12, 13]. Additionally, S. haematobium is responsible of egg-induced pathological lesions and associated symptoms in both men and women [14, 15].

An active UGS could be detected through observation of eggs in urine sediments and/or tissue biopsies [16]. For the aim of determining hotspots and control strategies, World Health Organization (WHO) has recommended microscopic-based poly-carbonate filter examination for urinary eggs as well as dipstick assays for urinary heme detection [17, 18]. Serodiagnostic assays identifying antibodies against worm antigens may demonstrate valuable credibility in symptomatic travelers, whereas they usually fail to differentiate active or previous infections, unless those employing circulating antigens [19, 20]. An encouraging degree of sensitivity and specificity have been gained in utilization of molecular assays such as polymerase chain reaction (PCR) for schistosome detection in human serum and urine samples [21]. This method is, also, beneficial for vaginal lavage analysis, revealing the likely traits of the genital schistosomiasis [22].

A very large number of female urinary schistosomiasis (FUS) studies were performed during the last two decades [23]. The emphasis of the present systematic review and meta-analysis was on the published literature during the last 5 years (2016–2020), in order to define the latest status of FUS and its prevalence based on examined subgroups. The novel findings of the present study may alert clinicians to the prevalence of this important helminthiasis and its associated consequences on the genitourinary system of infected female individuals.

Methods
The present systematic review and meta-analysis was accomplished on the basis of Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [24] (Additional file 1).

Information sources and systematic searching
Major English databases including Scopus, PubMed, Web of Science and Google Scholar were systematically searched for articles evaluating the prevalence of FUS worldwide and published during a 5-year time period, from January 2016 until the end of 2020. This procedure was conducted using the following keywords alone or in combination, using advanced search option in most databases and Medical Subject Heading (MeSH) option in PubMed databases: “Urinary Schistosomiasis” AND “Prevalence” OR “Epidemiology” AND “Female” OR “Women” OR “Girl”, where “AND” and/or “OR” are Boolean operators. Hand-searching of the bibliographic list of related papers was an additional task to more cover those papers not found via database exploration. Briefly, title and abstract of the literature were accurately reviewed (H.M. and M.F.), relevant papers were included, and upon duplicate removal, full-texts of eligible papers were retrieved (T.N.). Any disagreements were obviated by discussion and consensus with the leading researchers (M.SH and A.A.).

Inclusion/exclusion criteria and data collection
Specific inclusion criteria were determined in order to thoroughly gather relevant peer-reviewed cross-sectional studies and conference reports limited to women population in a 5-year time period (2016–2020). Only those papers with specified sample size and number of FUS-positive women, diagnosed either by microscopic, filtration, sedimentation and/or molecular techniques were included in current systematic review. Other study types (case reports, letters, reviews), studies evaluating animals or other Schistosomal infections, investigations without sample size/prevalence rates or lacking full-texts were all excluded from the present systematic review and meta-analysis. Finally, a pre-designed Microsoft Excel Spreadsheet® was used to extract the required information (E.J. and S.B.), as follows: first author’s last name, publication year, start and end years of studies, study type, country, province, city, sample type, diagnostic method, sample size, positive number of infected cases and clinical symptoms (hematuria and proteinuria).

Quality assessment
In the present systematic review, the Newcastle–Ottawa scale was employed to assess the quality of included studies. Those papers with the scores of <3.5, 3.6–5.25, and
5.26–7 were categorized as low-, moderate-, and high-quality papers, respectively [25].

**Data synthesis and meta-analysis**

Meta-analytical approach was done according to previous studies (S.B. and D.A.) using a random-effects model [26–28]. For all included studies, point estimates and their respective 95% confidence intervals (CIs) of weighted prevalence were calculated. Heterogeneity among these studies or variation in study outcomes was visualized by drawing forest plots, calculated by $I^2$ and Cochrane’s Q tests [29, 30]. The subgroup analysis was performed based on year, country, sample type, symptoms and diagnostic methods. The presence of publication bias was estimated by using Egger’s regression test [31]. This kind of bias, if present, skews the results and published reports are not a representative sample of the available evidence anymore. The trim-and-fill method was, also, used to “estimate the number of missing studies that might exist in a meta-analysis and the effect that these studies might have had on its outcome” [32]. $P$-values less than 0.05 were considered statistically significant.

All analytical functions were applied by Comprehensive Meta-analysis (CMA) version 2.2. (Biostat Inc., USA).

**Results**

The flow diagram of the systematic search process and inclusion of relevant papers is shown in Fig. 1. Initially, 3537 datasets were identified through comprehensive database exploration. After removing duplicates (1821) and those with irrelevant title and abstract (1571), 145 datasets were finally assessed for eligibility. Among these, 35 datasets were excluded with reasons (review papers, theses, conference papers and studies with confusing data) and 3 additional datasets were added through manual searching. Therefore, 106 articles containing 113 datasets were finally included in our meta-analysis (Table 1) [33–139].

Finally, 113 datasets evaluating 40,531 individuals were included in the present review. Among these, 11,308 individuals were shown to be affected by FUS and based on the random-effects model meta-analysis, the pooled prevalence of FUS was 17.5% (95% CI: 14.8–20.5%). The included studies demonstrated a strong heterogeneity ($I^2 = 98.12\%$, $P < 0.01$) (Additional file 2). Publication
| No. | References | Country | Province/city        | Time of data collection | Sample type | Method                                                                 | Sample size | Positive no | Quality assessment score |
|-----|------------|---------|----------------------|-------------------------|-------------|------------------------------------------------------------------------|-------------|-------------|-------------------------|
| 1   | Awosolu, 2020 [56] | Nigeria | Osun and Kwara       | 2012                    | Urine       | Filtrations and microscopic examination                              | 258         | 122         | 5                       |
| 2   | Olayinka, 2020 [112] | Nigeria | Ogun                 | 2015–2017               | Urine       | Microscopic examination                                               | 280         | 42          | 6                       |
| 3   | Awosolu, 2019 [55] | Nigeria | Ikota                | 2015                    | Urine       | Microscopic examination                                               | 74          | 20          | 7                       |
| 4   | Otuneme, 2019 [118] | Nigeria | Ogun                 | 2017                    | Urine       | Microscopic examination                                               | 47          | 39          | 5                       |
| 5   | Muhammad, 2019 [101] | Nigeria | Sokoto NR            | 2017                    | Urine       | Microscopic examination                                               | 107         | 47          | 5                       |
| 6   | Sule, 2019 [129] | Nigeria | Kano NR              | 2017                    | Urine       | Microscopic examination                                               | 56          | 0           | 6                       |
| 7   | Idris, 2019 [87] | Nigeria | New-Bussa NR         | 2017                    | Urine       | Microscopic examination                                               | 24          | 2           | 7                       |
| 8   | Geraji, 2019 [81] | Nigeria | Jalingo              | 2017                    | Urine       | Microscopic examination                                               | 86          | 13          | 7                       |
| 9   | Adamu, 2019 [36] | Nigeria | Kaduna               | 2017                    | Urine       | Microscopic examination                                               | 136         | 4           | 7                       |
| 10  | Ngwamah, 2019 [105] | Nigeria | Adamawa NR           | 2016                    | Urine       | Microscopic examination                                               | 679         | 141         | 7                       |
| 11  | Aribodor, 2019 [51] | Nigeria | Enugu                | 2016                    | Urine       | Microscopic examination                                               | 121         | 17          | 7                       |
| 12  | Sobande, 2019 [128] | Nigeria | Ogun NR              | 2017                    | Urine       | Microscopic examination                                               | 84          | 40          | 6                       |
| 13  | Obisike, 2019 [110] | Nigeria | Benue                | 2017                    | Urine       | Membrane filtration and (sedimentation) microscopic examination       | 84          | 20          | 5                       |
| 14  | Ahmed, 2019 [40] | Nigeria | Katsina NR           | 2016                    | Urine       | Membrane filtration and (sedimentation) microscopic examination       | 68          | 15          | 6                       |
| 15  | Adenbigbe, 2019 [37] | Nigeria | Kwara NR             | 2016                    | Urine       | Microscopic examination                                               | 883         | 293         | 7                       |
| 16  | Norioede, 2018 [106] | Nigeria | Edo NR               | 2016                    | Urine       | Microscopic examination                                               | 109         | 75          | 5                       |
| 17  | Bishop, 2016 [164] | Nigeria | Kaduna NR            | 2016                    | Urine       | Microscopic examination                                               | 92          | 5           | 6                       |
| 18  | Mohammed, 2018 [95] | Nigeria | Sokoto              | 2016                    | Urine       | Microscopic examination                                               | 51          | 18          | 5                       |
| 19  | Akinneye, 2018 [43] | Nigeria | Ondo NR              | 2017                    | Urine       | Microscopic examination                                               | 202         | 22          | 5                       |
| 20  | Alabi, 2018 [46] | Nigeria | Ogun NR              | 2017                    | Urine       | Microscopic examination                                               | 73          | 36          | 6                       |
| 21  | Damen, 2018 [68] | Nigeria | Plateau NR           | 2017                    | Urine       | Microscopic examination                                               | 7           | 1           | 6                       |
| 22  | Yauba, 2018 [138] | Nigeria | Maiduguri            | 2014–2015               | Urine       | Microscopic examination                                               | 180         | 113         | 7                       |
| 23  | Abdulkareem, 2018 [34] | Nigeria | Kwara NR             | 2016                    | Urine       | Microscopic examination                                               | 309         | 131         | 7                       |
| 24  | Oladeinde, 2018 [111] | Nigeria | Edo                 | 2017                    | Urine       | Microscopic examination                                               | 98          | 8           | 6                       |
| 25  | Ebong, 2018 [70] | Nigeria | Akwa Ibom            | 2017                    | Urine       | Microscopic examination                                               | 199         | 5           | 7                       |
Table 1 (continued)

| No. | References | Country       | Province/city | Time of data collection | Sample type | Method                                      | Sample size | Positive no | Quality assessment score |
|-----|------------|---------------|---------------|-------------------------|-------------|---------------------------------------------|-------------|--------------|--------------------------|
| 26  | Akeju Adebayo, 2018 [42] | Nigeria       | Ondo          | NR                      | Urine       | Microscopic examination                     | 1022        | 441          | 5                        |
| 27  | Oluwole, 2018 [114]       | Nigeria       | Ogun          | 2013                    | Urine       | Microscopic examination                     | 1034        | 43           | 6                        |
| 28  | Adevale, 2018 [38]        | Nigeria       | Ondo          | NR                      | Urine       | Microscopic examination                     | 190         | 44           | 6                        |
| 29  | Nwachukwu, 2018 [107]     | Nigeria       | Imo           | 2014–2016               | Urine       | Test strip and filtration                   | 1125        | 57           | 7                        |
| 30  | Nwachukwu, 2018 [108]     | Nigeria       | Ebonyi        | 2016–2017               | Urine       | Microscopic examination                     | 254         | 8            | 7                        |
| 31  | Duwa, 2018 [69]           | Nigeria       | Kano          | 2018                    | Urine       | Microscopic examination                     | 105         | 8            | 5                        |
| 32  | Babagana, 2018 [57]       | Nigeria       | Borno         | NR                      | Urine       | Microscopic examination                     | 180         | 31           | 7                        |
| 33  | Mohammed, 2018 [94]       | Nigeria       | Kebbi         | 2016                    | Urine       | (Filtration) Microscopic examination        | 81          | 16           | 5                        |
| 34  | Oluwole, 2018 [114]       | Nigeria       | Ogun          | NR                      | Urine and vaginal lavage | Microscopic and gynecologic examination | 317         | 149          | 6                        |
| 35  | Kenneth, 2017 [92]        | Nigeria       | Edo           | NR                      | Urine       | Microscopic examination                     | 76          | 6            | 7                        |
| 36  | Birm, 2017 [61]           | Nigeria       | Adamawa       | NR                      | Urine       | Microscopic examination                     | 90          | 42           | 5                        |
| 37  | Amoo, 2017 [47]           | Nigeria       | Ogun          | NR                      | Urine       | Microscopic examination                     | 160         | 61           | 6                        |
| 38  | Paul, 2017 [119]          | Nigeria       | Cross River   | NR                      | Urine       | Microscopic examination                     | 140         | 24           | 5                        |
| 39  | Orpin, 2017 [116]         | Nigeria       | Katsina       | NR                      | Urine       | Microscopic examination                     | 145         | 12           | 5                        |
| 40  | Ekanem, 2017 [71]         | Nigeria       | South-South   | 2011                    | Urine       | Microscopic examination                     | 177         | 27           | 6                        |
| 41  | Akpan, 2017 [45]          | Nigeria       | Cross River   | NR                      | Urine       | Microscopic examination                     | 208         | 34           | 7                        |
| 42  | Elom, 2017 [73]           | Nigeria       | Ebonyi        | NR                      | Urine       | Microscopic examination                     | 147         | 33           | 7                        |
| 43  | Akpan, 2017 [44]          | Nigeria       | Cross River   | NR                      | Urine       | Microscopic examination                     | 122         | 1            | 7                        |
| 44  | Abubakar, 2017 [35]       | Nigeria       | Jigawa        | 2015                    | Urine       | Microscopic examination                     | 65          | 46           | 7                        |
| 45  | Dalhat, 2017 [67]         | Nigeria       | Sokoto        | NR                      | Urine       | Microscopic examination                     | 140         | 41           | 7                        |
| 46  | Emmanuel, 2017 [75]       | Nigeria       | Benue         | 2014                    | Urine       | Microscopic examination                     | 207         | 77           | 6                        |
| 47  | Wokem, 2017 [135]         | Nigeria       | Abia          | NR                      | Urine       | Microscopic examination                     | 570         | 215          | 7                        |
| 48  | Anorue, 2017 [49]         | Nigeria       | Ebonyi        | 2002–2003               | Urine       | Microscopic examination                     | 1367        | 640          | 6                        |
| 49  | Orpin, 2016 [117]         | Nigeria       | Benue         | NR                      | Urine       | Microscopic examination                     | 104         | 8            | 7                        |
| 50  | Onile, 2016 [115]         | Nigeria       | Eggua         | 2012–2013               | Urine       | Microscopic examination                     | 178         | 45           | 7                        |
| 51  | Houmsou, 2016 [86]        | Nigeria       | Taraba        | NR                      | Urine       | Microscopic examination                     | 529         | 231          | 5                        |
| No. | References                      | Country | Province/city | Time of data collection | Sample type | Method                        | Sample size | Positive no | Quality assessment score |
|-----|---------------------------------|---------|---------------|--------------------------|-------------|-------------------------------|-------------|-------------|--------------------------|
| 52  | Goodhead, 2016 [83]             | Nigeria | River         | NR                       | Urine       | Microscopic examination      | 76          | 17          | 7                        |
| 53  | Usman, 2016 [133]               | Nigeria | Bauchi        | NR                       | Urine       | Microscopic examination      | 300         | 58          | 7                        |
| 54  | Dahesh, 2016 [66]               | Nigeria | Giza          | 2016                     | Urine       | Microscopic examination      | 582         | 12          | 7                        |
| 55  | Igbeneghu, 2016 [88]            | Nigeria | Osun          | 2016                     | Urine       | Microscopic examination      | 154         | 60          | 7                        |
| 56  | Nafiu, 2016 [104]               | Nigeria | Niger         | 2016                     | Urine       | Microscopic examination      | 97          | 9           | 6                        |
| 57  | Abah, 2016 [33]                 | Nigeria | River         | 2016                     | Urine       | Microscopic examination      | 184         | 23          | 5                        |
| 58  | Umar, 2016 [132]                | Nigeria | Kano          | NR                       | Urine       | Microscopic examination      | 20          | 9           | 5                        |
| 59  | Atalabi, 2016 [52]              | Nigeria | Katsina       | NR                       | Urine       | Microscopic examination      | 240         | 14          | 6                        |
| 60  | Houmsou, 2016 [86]              | Nigeria | Taraba        | NR                       | Urine       | Microscopic examination      | 510         | 3           | 7                        |
| 61  | Nwibari, 2016 [165]             | Nigeria | Plateau       | NR                       | Urine       | Microscopic examination      | 134         | 6           | 5                        |
| 62  | Omoruyi, 2016 [166]             | Nigeria | Edo           | NR                       | Urine       | Microscopic examination      | 77          | 4           | 6                        |
| 63  | Morenikeji, 2016 [99]           | Nigeria | Ogun          | NR                       | Urine       | Microscopic examination      | 79          | 60          | 6                        |
| 64  | Bashir, 2016 [60]               | Nigeria | Jigawa        | NR                       | Urine       | Microscopic examination      | 31          | 2           | 7                        |
| 65  | Ganau, 2016 [79]                | Nigeria | Sokoto        | NR                       | Urine       | Microscopic examination      | 58          | 24          | 5                        |
| 66  | Musa, 2016 [102]                | Nigeria | Kaduna        | NR                       | Urine       | Microscopic examination      | 131         | 13          | 6                        |
| 67  | Ajakaye, 2016 [41]              | Nigeria | Ondo          | NR                       | Urine       | Microscopic examination      | 404         | 50          | 7                        |
| 68  | Mong, 2016 [98]                 | Nigeria | Abia          | NR                       | Urine       | Microscopic examination      | 129         | 13          | 7                        |
| 69  | Atalabi, 2016 [53]              | Nigeria | Katsina       | 2015                     | Urine       | Microscopic examination      | 317         | 23          | 6                        |
| 70  | Oluwatoyin, 2016 [113]*         | Nigeria | Ibadan        | NR                       | Urine       | Microscopic examination      | 507         | 1           | 7                        |
| 71  | Oluwatoyin, 2016 [113]          | Nigeria | Ibadan        | NR                       | Urine       | Microscopic examination      | 507         | 28          | 6                        |
| 72  | Bishop, 2016 [63]               | Nigeria | Kaduna        | NR                       | Urine       | Microscopic examination      | 251         | 39          | 5                        |
| 73  | Maki, 2020 [93]                 | Sudan   | Darfur        | 2018                     | Urine       | Microscopic examination      | 55          | 39          | 6                        |
| 74  | Qutoof, 2019 [122]              | Sudan   | Khartoum      | NR                       | Urine       | Microscopic examination      | 589         | 2           | 5                        |
| 75  | Elsiddig, 2019 [74]             | Sudan   | White Nile    | 2011                     | Urine       | Microscopic examination      | 162         | 67          | 6                        |
| 76  | Hajissa, 2018 [85]              | Sudan   | Khartoum      | 2017–2018                | Urine       | Microscopic examination      | 95          | 11          | 6                        |
| 77  | Mohammed, 2018 [96]             | Sudan   | White Nile    | NR                       | Urine       | Microscopic examination      | 175         | 97          | 7                        |
| 78  | Talab, 2018 [167]               | Sudan   | White Nile    | 2014                     | Urine       | Microscopic examination      | 174         | 97          | 5                        |
| No. | References | Country | Province/city | Time of data collection | Sample type | Method | Sample size | Positive no | Quality assessment score |
|-----|------------|---------|---------------|-------------------------|-------------|--------|-------------|-------------|--------------------------|
| 79  | Sulieman, 2017 [130] | Sudan | River Nile | 2016 | Urine | (Sedimentation) Microscopic examination | 191 | 1 | 6 |
| 80  | Sabah Alzain Mohamed, 2017 [124] | Sudan | El khiar | 2016 | Urine | Microscopic examination | 76 | 7 | 5 |
| 81  | Afifi, 2016 [39] | Sudan | Kassala | 2013 | Urine | Microscopic examination | 1238 | 172 | 6 |
| 82  | Elhusein, 2016 [72] | Sudan | Gezira | 2016 | Urine | Microscopic examination | 29 | 0 | 7 |
| 83  | Shukla, 2019 [126] | South Africa | KwaZulu-Natal | 2011–2013 | Urine and cervico-vaginal lavage | Microscopic examination | 933 | 256 | 5 |
| 84  | Galappaththi-Arachchige, 2018 [78] | South Africa | KwaZulu-Natal | NR | Urine | Microscopic examination | 1123 | 292 | 5 |
| 85  | Kabuyaya, 2017 [89] | South Africa | uMkhanyakude | 2015 | Urine | Microscopic examination | 199 | 73 | 7 |
| 86  | Galappaththi-Arachchige, 2016 [168] | South Africa | KwaZulu-Natal | NR | Urine | Microscopic examination | 883 | 270 | 6 |
| 87  | Pillay, 2016 [169] | South Africa | KwaZulu-Natal | 2010–2012 | vaginal lavages and Urine | PCR | 394 | 38 | 7 |
| 88  | South Africa | KwaZulu-Natal | 2010–2012 | Urine | PCR | 394 | 91 | 7 |
| 89  | South Africa | KwaZulu-Natal | 2010–2012 | Urine | Microscopic examination | 394 | 78 | 7 |
| 90  | Fokuo, 2020 [76] | Ghana | Asutsuare | 2014 | Urine | Microscopic examination | 59 | 8 | 6 |
| 91  | Arhin-Wiredu, 2019 [50] | Ghana | Akyemansa | 2014 | Urine | Microscopic examination | 161 | 10 | 6 |
| 92  | Nyarko, 2018 [109] | Ghana | different municipal-ities | 2016 | Urine | Microscopic examination | 173 | 7 | 6 |
| 93  | Boye, 2016 [65] | Ghana | Apewosika and Putubiw | 2013 | Urine | Microscopic examination | 114 | 16 | 5 |
| 94  | Wilkinson, 2018 [134] | Malawi | Lilongwe | 2013 | Urine | Microscopic examination | 96 | 2 | 6 |
| 95  | Kayuni, 2017 [91] | Malawi | Mangochi | 2012 | Urine | Microscopic examination | 226 | 29 | 6 |
| 96  | Moyo, 2016 [100] | Malawi | Nkhotakota | NR | Urine | Microscopic examination | 51 | 6 | 6 |
| 97  | Yamery, 2018 [137] | Egypt | El-Fayoum | NR | Urine | Microscopic examination | 487 | 33 | 7 |
| 98  | Ghieith, 2017 [82] | Egypt | Beni Suef | NR | Urine | Microscopic examination | 220 | 0 | 5 |
| 99  | Kaiglova, 2020 [90] | Kenya | Kwale | 2018 | Urine | Microscopic examination | 323 | 47 | 5 |
| 100 | Mutsaka-Makuvaza, 2019 [103] | Zimbabwe | Mashonaland | 2010 | Urine | Microscopic examination | 569 | 96 | 6 |
| 101 | Woldegerima, 2019 [136] | Ethiopia | Sanja | 2017–2018 | Urine | Microscopic examination | 189 | 53 | 7 |
| 102 | Phillips, 2018 [120] | Mozambique | Cabo Delgado | 2011 | Urine | Microscopic examination | 7538 | 4372 | 7 |
| 103 | Gbalegba, 2017 [80] | Mauritania | Kaedi | 2014–2015 | Urine | Microscopic examination | 1064 | 54 | 6 |
bias was checked by Egger’s regression test, showed that it may have a substantial impact on total prevalence estimate (Egger’s bias: 7.5, *P* < 0.01) (Fig. 2). Since the heterogeneity of included studies was very high, meta-regression of subgroups such as year, country, type of sample, type of symptoms, and diagnostic method were used to overcome heterogeneity (Table 2). According to subgroup analysis of included data, the prevalence of FUS demonstrated a relatively but worrying increasing trend from 14.6% (95% CI: 11.3–18.6%) in 2016 to 28.6% (95% CI: 13.1–51.6%) in 2020, respectively. In total, studies were conducted in 21 countries, including Nigeria (73 datasets), Sudan (10 datasets), South Africa (7 datasets), Ghana (4 datasets), Malawi (3 datasets), Egypt (2 datasets), as well as Kenya, Zimbabwe, Ethiopia, Mozambique, Mauritania, Zambia, Morocco, Cameroon, Gabon, Chad, Guinea-Bissau, Senegal, Madagascar, Sierra Leone and Burkina Faso (one dataset per country). The highest prevalence rates were estimated for women in Mozambique with 58% (95% CI: 56.9–59.1%) (one study), while female individuals in Chad had the lowest prevalence rate 1.0% (95% CI: 0.1–7.0%). Year-based prevalence for the six most studied countries, showed no determined pattern for frequency of FUS, however, a relatively decreasing pattern of prevalence was recorded for Malawi (three studies) (Figs. 3, 4, 5, 6, 7, 8). Regarding sample type, urine and vaginal lavage were gathered from examined women, with vaginal lavage demonstrating a higher frequency of FUS [25.0% (95% CI: 11.4–46.1%)] than urine specimen [17.2% (95% CI: 14.5–20.3%)]. Reportedly, hematuria and proteinuria as the most prominent symptoms of FUS were estimated in some studies, showing 19.4% (95% CI: 12.2–29.4%) and 13.6% (95% CI: 6.69–24.8%) prevalence rates, correspondingly. Direct microscopy was the most frequently utilized diagnostic test, yielding a relatively higher prevalence 17.1% (95% CI: 14.5–20.1%) than PCR method 15.3% (95% CI: 6.1–33.2%); however, only two studies employed molecular method. Additional microscopy-based procedures were filtration and sedimentation, which in detail yielded a prevalence rate of 18.2% (95% CI: 5.9–43.9%) and 11.4% (95% CI: 3.6–30.9%), respectively. Altogether, subgroup analysis revealed that there were statistically significant differences between the overall prevalence of FUS and year. Of note, the quality score of the included papers is provided in Additional file 3.

**Discussion**

Helminth-induced diseases are ancient catastrophic phenomena in humans, some dating back to pre-biblical era, with huge but chronic and snaky damages in nature [140]. Schistosomiasis or bilharziasis is one of the most important water-borne helminthic diseases, which have always been interconnected with archaic civilizations over the
millennia, and it is still a global public health concern due to its astonishing, complex life cycle [141, 142]. Among schistosome species infecting humans, *S. haematobium* worms are the causative agents of UGS which localize within draining venous complex of the pelvic organs such as uterus, cervix and the bladder [143]. These worms are highly prolific, releasing about 3000 eggs/day, half of which are excreted through urine, while the rest are lodged within vasculature of urogenital organs. Immune-mediated pathologic processes elicited against tissue-embedded ova result in granulomatous inflammation, tissue destruction and the so-called “sandy patches” as fibrotic nodules [16]. With respect to the significance of UGS and large number of affected individuals, the present systematic review and meta-analysis was contrived in order to reveal the latest status of urinary schistosomiasis in women population based on published literature in the last 5 years and provide a premise for future clinical directions on women health.

The required information was assembled from available full-texts published between 2016 and 2020 and their overall estimates were assessed through a meticulous meta-analytical method. During last 5 years, 11,308 out of 40,531 women were suffering from urinary schistosomiasis, contributing to the global weighted prevalence of 17.5% (95% CI: 14.8–20.5%). Interestingly, all cases in the last 5 years were from African countries. This continent is probably known as the “cradle of schistosomes”, since African great lakes provide a favorable milieu for the optimum evolution of both parasites and their respective intermediate hosts [144]. Schistosomiasis may have spread to Africa, particularly Egypt, in virtue of monkey importation and slave trades during fifth dynasty of pharaohs [145]. Based on our results obtained from limited number of heterogeneous investigations included in the present meta-analysis, a large number of studies (73) on FUS were done in a western African nation, Nigeria, whereas the highest prevalence rate was estimated for women in Mozambique with 58% (95% CI: 56.9–59.1%) (one study), a country in the southeast coast of Africa. Nigerian researchers have shown a substantial effort in search of urinary schistosomiasis during last 5 years by conducting 73 datasets, which could be a favorable layout for other African countries [143]. Nevertheless, the true picture of FUS prevalence throughout African territories in a 5-year time period was not accurately captured, since out of 21 countries examining female individuals, only 6 countries had sufficient studies to perform meta-analytical approach and most of the remaining had only one investigation per country. Moreover, a statistically significant gradual increase was observed in FUS prevalence based on publication year of the included literature, from

---

**Fig. 2** A bias assessment plot from Egger for the FUS prevalence (2016–2020)
2016 until the end of 2020, ranging from 14.6% (95% CI: 11.3–18.6%) to 28.6% (95% CI: 13.1–51.6%), respectively. However, no such an increasing trend was observed in year-based analysis of each country; even the prevalence relatively decreased in Malawi, though only three studies were involved in this country. Such findings derived from limited number of included studies in current review may be interpreted as a spread of the endemic situation of FUS, or as a result of the increased understanding about FUS among health care professionals in each country. Nevertheless, more in-depth studies are required to further elucidate this issue.

The characteristic symptoms of UGS were prominently reported among examined women, so that a higher prevalence rate was recorded for hematuria with 19.4% (95% CI: 12.2–29.4%), in comparison to 13.6% (95% CI: 6.69–24.8%) frequency of proteinuria. As previously mentioned, disease morbidity largely results from entrapped eggs, which strongly induce a granulomatous immune response [146], characterized by Th2-type lymphocytes, alternatively activated macrophages and eosinophils [147, 148]. Thereby, the eggs are immunologically confined within the so-called "granulomas", containing proteolytic enzymes of egg origin that barricade tissue necrosis [149]. In accordance with our finding, hematuria is considered as a defining symptom in *S. haematobium* infection, mostly being accompanied by suprapubic ailment, burning micturition as well as frequent urination [150]. Poor immunoregulatory mechanisms in response to eggs provoke a lasting fibrotic reaction in the urinary tract of infected individuals [151]. The resulting obstructive uropathy elicit subsequent dreadful consequences such as the hydrourerter and hydronephrosis [152]. The latter is the milestone in ascending bacterial superinfections, renal dysfunctions and the ensuing proteinuria [153]. The consequences are more horrific in affected women, since the proximity of vesical and genital venous plexuses facilitates easy migration of parasites and/or eggs, leading to harsh outcomes regarding women’s reproductive health [154–156]. The subsequent lesions in genital organs, from ovaries to vagina, may be associated with pain and stress, allowing human immunodeficiency virus-1 (HIV-1) to simply access sub-epithelial target cells [157]. In a recently published meta-analysis, the chance of acquiring HIV among people suffering from schistosomiasis was 2.3-fold (95% CI: 1.2–4.3%) higher than non-infected

### Table 2

| Subgroup variable | Prevalence % (95% CI) | $I^2$ (%) | Heterogeneity (Q) | $P$-value | Interaction test ($X^2$) | $P$-value |
|------------------|----------------------|---------|------------------|--------|-------------------|--------|
| **Year**         |                      |         |                  |        |                   |        |
| 2016             | 14.6 (11.3–18.6)     | 96.3%   | 1034.7           | <0.01  | 375.3             | <0.01  |
| 2017             | 17.5 (12–24.9)       | 97.8%   | 1055.2           | <0.01  |                   |        |
| 2018             | 19.0 (13.1–26.7)     | 98.8%   | 2179.6           | <0.01  |                   |        |
| 2019             | 21.7 (16.8–27.5)     | 93.4%   | 274.7            | <0.01  |                   |        |
| 2020             | 28.6 (13.1–51.6)     | 97.1%   | 138.2            | <0.01  |                   |        |
| **Country**      |                      |         |                  |        |                   |        |
| Ghana            | 9.1 (6.8–12.2)       | 73.46%  | 11.31            | <0.01  |                   |        |
| Malawi           | 11.4 (8.0–15.4)      | 70.62%  | 6.81             | <0.01  |                   |        |
| Nigeria          | 21.1 (17.6–25.0)     | 96.9%   | 2337.91          | <0.01  |                   |        |
| South Africa     | 27.4 (25.6–29.2)     | 92.53%  | 80.36            | <0.01  |                   |        |
| Sudan            | 55.8 (43.9–67.1)     | 97.59%  | 374.17           | <0.01  | 430.6             | <0.01  |
| Egypt            | 1.7 (0.1–32.8)       | 83.57%  | 5.90             | <0.01  |                   |        |
| **Type of sample** |                    |         |                  |        |                   |        |
| Urine            | 17.2 (14.5–20.3)     | 98.11%  | 5949.4           | <0.01  | 1285.2            | >0.05  |
| Vaginal lavage   | 25.0 (11.4–46.1)     | 98.2%   | 110.40           | <0.01  |                   |        |
| **Type of symptoms** |                |         |                  |        |                   |        |
| Hematuria        | 19.4 (12.2–29.4)     | 92.33%  | 52.19            | <0.01  | 82.4              | <0.01  |
| Proteinuria      | 13.6 (6.69–24.8)     | –       | 0.00             | =1.00  |                   |        |
| **Diagnostic method** |                |         |                  |        |                   |        |
| Direct microscopy| 17.1 (14.5–20.1)     | 98.1%   | 6013             | <0.01  | 350.6             | <0.01  |
| Filtration and microscopy | 18.2 (5.9–43.9) | 99.1% | 563.1 | <0.01 | |
| PCR              | 15.3 (6.1–33.2)      | 95.9%   | 24.64            | <0.01  |                   |        |
| Sedimentation and microscopy | 11.4 (3.6–30.9) | 96.6% | 59.5 | <0.01 | |
### Fig. 3 Forest plot of year-based prevalence in Nigeria (2016–2020)

| Group by Subgroup within study | Study name | Subgroup within study | Event rate | Lower limit | Upper limit | Z-value | p-value |
|--------------------------------|------------|-----------------------|------------|-------------|------------|---------|---------|
| 2016:00 | Ojo et al. (2016) | 2016:00 | 0.077 | 0.039 | 0.146 | -4.733 | 0.000 |
| 2017:00 | Ojo et al. (2016) | 2017:00 | 0.253 | 0.194 | 0.322 | -8.284 | 0.000 |
| 2018:00 | Ojo et al. (2016) | 2018:00 | 0.427 | 0.395 | 0.459 | -29.050 | 0.000 |
| 2019:00 | Ojo et al. (2016) | 2019:00 | 0.624 | 0.583 | 0.666 | -25.668 | 0.000 |
| 2020:00 | Ojo et al. (2016) | 2020:00 | 0.933 | 0.856 | 0.999 | -17.258 | 0.000 |
| 2016:00 | Ojo et al. (2016) | 2016:00 | 0.124 | 0.095 | 0.160 | -12.055 | 0.000 |
| 2017:00 | Ojo et al. (2016) | 2017:00 | 0.101 | 0.069 | 0.146 | -2.163 | 0.031 |
| 2018:00 | Ojo et al. (2016) | 2018:00 | 0.075 | 0.060 | 0.097 | -11.768 | 0.000 |
| 2019:00 | Ojo et al. (2016) | 2019:00 | 0.082 | 0.050 | 0.114 | -6.220 | 0.000 |
| 2020:00 | Ojo et al. (2016) | 2020:00 | 0.116 | 0.056 | 0.176 | -3.717 | 0.000 |

### Fig. 4 Forest plot of year-based prevalence in Sudan (2016–2020)

| Group by Subgroup within study | Study name | Subgroup within study | Event rate | Lower limit | Upper limit | Z-value | p-value |
|--------------------------------|------------|-----------------------|------------|-------------|------------|---------|---------|
| 2016:00 | Emoka et al. (2016) | 2016:00 | 0.077 | 0.039 | 0.146 | -4.733 | 0.000 |
| 2017:00 | Emoka et al. (2016) | 2017:00 | 0.253 | 0.194 | 0.322 | -8.284 | 0.000 |
| 2018:00 | Emoka et al. (2016) | 2018:00 | 0.427 | 0.395 | 0.459 | -29.050 | 0.000 |
| 2019:00 | Emoka et al. (2016) | 2019:00 | 0.624 | 0.583 | 0.666 | -25.668 | 0.000 |
| 2020:00 | Emoka et al. (2016) | 2020:00 | 0.933 | 0.856 | 0.999 | -17.258 | 0.000 |
| 2016:00 | Emoka et al. (2016) | 2016:00 | 0.124 | 0.095 | 0.160 | -12.055 | 0.000 |
| 2017:00 | Emoka et al. (2016) | 2017:00 | 0.101 | 0.069 | 0.146 | -2.163 | 0.031 |
| 2018:00 | Emoka et al. (2016) | 2018:00 | 0.075 | 0.060 | 0.097 | -11.768 | 0.000 |
| 2019:00 | Emoka et al. (2016) | 2019:00 | 0.082 | 0.050 | 0.114 | -6.220 | 0.000 |
| 2020:00 | Emoka et al. (2016) | 2020:00 | 0.116 | 0.056 | 0.176 | -3.717 | 0.000 |

---

Fig. 3 Forest plot of year-based prevalence in Nigeria (2016–2020)

Fig. 4 Forest plot of year-based prevalence in Sudan (2016–2020)
Fig. 5 Forest plot of year-based prevalence in South Africa (2016–2020)

| Group by Study name | Subgroup within study | Event rate | Event rate | Event rate and 95% CI | Relative weight |
|---------------------|-----------------------|------------|------------|------------------------|-----------------|
|                     |                       | Event rate | Lower limit | Upper limit | p-value |                       |               |
| 2016.00             | (Guluphopiti-Anshulgie et al., 2016) | 0.304 | 0.234 | 0.374 | 0.150 | 0.310 | 0.000 | 25.64 |
| 2016.00             | (Flibig et al., 2016) | 0.089 | 0.075 | 0.103 | 0.130 | 0.110 | 0.000 | 25.91 |
| 2016.00             | (Flibig et al., 2016a) | 0.231 | 0.202 | 0.257 | 0.192 | 0.273 | 0.100 | 25.14 |
| 2016.00             | (Flibig et al., 2016b) | 0.198 | 0.162 | 0.230 | 0.182 | 0.240 | 0.110 | 25.00 |
| 2017.00             | (Sakbyanga et al., 2017) | 0.367 | 0.303 | 0.436 | 0.816 | 0.911 | 0.000 | 100.00 |
| 2018.00             | (Guluphopiti-Anshulgie et al., 2016) | 0.268 | 0.235 | 0.286 | 0.235 | 0.286 | 0.150 | 100.00 |
| 2018.00             | (Guluphopiti-Anshulgie et al., 2016a) | 0.268 | 0.235 | 0.286 | 0.235 | 0.286 | 0.150 | 100.00 |
| 2019.00             | (Sheikh et al., 2019) | 0.274 | 0.254 | 0.295 | 0.257 | 0.295 | 0.150 | 100.00 |
| Overall             |                       | 0.274 | 0.256 | 0.292 | 0.256 | 0.292 | 0.150 | 100.00 |

Fig. 6 Forest plot of year-based prevalence in Ghana (2016–2020)

| Group by Study name | Subgroup within study | Event rate | Event rate | Event rate and 95% CI | Relative weight |
|---------------------|-----------------------|------------|------------|------------------------|-----------------|
|                     |                       | Event rate | Lower limit | Upper limit | p-value |                       |               |
| 2016.00             | (Boyd et al., 2016) | 0.140 | 0.088 | 0.217 | 0.140 | 0.217 | 0.000 | 100.00 |
| 2016.00             | (Nygard et al., 2016) | 0.140 | 0.088 | 0.217 | 0.140 | 0.217 | 0.000 | 100.00 |
| 2016.00             | (Nygard et al., 2016a) | 0.140 | 0.088 | 0.217 | 0.140 | 0.217 | 0.000 | 100.00 |
| 2019.00             | (Adi-Abdul et al., 2016) | 0.162 | 0.112 | 0.213 | 0.134 | 0.191 | 0.000 | 100.00 |
| 2019.00             | (Ade-Lei et al., 2016) | 0.162 | 0.112 | 0.213 | 0.134 | 0.191 | 0.000 | 100.00 |
| 2020.00             | (Fikos Heri et al., 2020) | 0.136 | 0.099 | 0.240 | 0.099 | 0.240 | 0.000 | 100.00 |
| 2020.00             | (Fikos Heri et al., 2020) | 0.136 | 0.099 | 0.240 | 0.099 | 0.240 | 0.000 | 100.00 |
| Overall             |                       | 0.136 | 0.099 | 0.240 | 0.099 | 0.240 | 0.000 | 100.00 |

Fig. 7 Forest plot of year-based prevalence in Malawi (2016–2020)

| Study name          | Event rate | Event rate | Event rate and 95% CI | Relative weight |
|---------------------|------------|------------|------------------------|-----------------|
|                     | Event rate | Lower limit | Upper limit | Z-value | p-value |                       |               |
| (Kooren et al., 2016) | 0.126 | 0.091 | 0.230 | 0.126 | 0.230 | 0.000 | 100.00 |
| (Kooren et al., 2016a) | 0.126 | 0.091 | 0.197 | 0.126 | 0.197 | 0.000 | 100.00 |
| (Kooren et al., 2016b) | 0.126 | 0.091 | 0.197 | 0.126 | 0.197 | 0.000 | 100.00 |
| (Kooren et al., 2016c) | 0.126 | 0.091 | 0.197 | 0.126 | 0.197 | 0.000 | 100.00 |
| Overall             | 0.126 | 0.091 | 0.197 | 0.126 | 0.197 | 0.000 | 100.00 |

Fig. 8 Forest plot of year-based prevalence in Egypt (2016–2020)
patients [158]. Finally, the affected women might experience painful intercourse (dyspareunia), fibrotic ovaries and/or granuloma-induced tubal blockage, all of which lead to the female infertility. Hence, FUS may lead to harsh reproductive outcomes that ultimately endangers the fecundity, fertility and pregnancy of women [159].

The result of the present meta-analysis highlighted that a higher prevalence of FUS was demonstrated by vaginal lavage (25.0% [95% CI: 11.4–46.1%]) than urine specimens (17.2% [95% CI: 14.5–20.3%]). Although there was not statistically significant difference between the total prevalence of FUS and sample type (P > 0.05). Moreover, the results of current review demonstrated that microscopy 17.1% (95% CI: 14.5–20.1%) contributed more to reveal the FUS prevalence than PCR method 15.3% (95% CI: 6.1–33.2%); nevertheless, only two studies utilized molecular method for diagnosis, and any deductions should accompany with caution. Notably, urine filtration (about 10 mL) that is routinely performed for egg detection was more efficient in detecting parasite eggs than sedimentation method, with 18.2% (95% CI: 5.9–43.9%) versus 11.4% (95% CI: 3.6–30.9%), respectively. Urine microscopy is the gold standard in detection of S. haematobium eggs in areas of endemicity [160]. However, it is not sensitive sufficiently for monitoring praziquantel therapeutic efficiency in mass drug administration (MDA) campaigns, particularly in low-transmission intensity areas, because weeks after adult worm elimination eggs are still observable in urine or some worms may have temporarily stopped shedding eggs [161]. Also, it lacks adequate sensitivity, due to the fact that eggs are only detectable in urine samples 2 months after infection onwards [162]. Therefore, it is highly recommended to carry out at least two follow-up visits and microscopic examination for more accurate diagnosis [163]. Additionally, in order to enhance the sensitivity and specificity and deter underestimation of the true disease burden, performing highly sensitive methods such as molecular techniques are inevitable [21]. As mentioned earlier, only two studies in the last 5 years used PCR method, which exhibited a remarkable prevalence rate for FUS, implicating the importance of such modalities in accurate detection of urinary schistosomiasis.

The present systematic review and meta-analysis met some limitations, including: (1) lack of adequate prevalence studies in countries other than Nigeria; (2) diagnosis of the infection mostly based on microscopic examination of urine samples; (3) inadequate number of molecular-based studies in the last 5 years, and (4) due to the nature of the systematic review and meta-analysis studies, which exclude some papers relied on a designed inclusion criteria, the provided results are only based on the information extracted from 113 datasets and any definite inference must accompany with caution. Inevitably, implementation of large-scale or nation-wide prevalence studies on FUS throughout African nations, particularly in neglected regions of the continent, using microscopy of urine specimen (gold standard method) coupled with unprecedented molecular approaches will more elucidate the true epidemiological picture of urinary schistosomiasis among women population. Consequently, such information benefits the clinicians for the prevention of the horrible sequelae of chronic FUS.

**Conclusion**

In conclusion, information provided in the present systematic review and meta-analysis showed that women in endemic territories in Africa are moderately at risk of acquiring FUS and its harsh consequences, including renal dysfunction, urinary bladder carcinoma as well as reproductive disorders such as dyspareunia and granuloma-induced infertility. Consequently, health assessment of FUS should be considered as a routine necessity for women in susceptible age groups such as those in active reproductive status and/or child-bearing age. Relying only on low-sensitivity microscopic results cannot rule out the presence of schistosomes in blood vessels. Hence, clinical assessment must be performed using gold standard methods, i.e., microscopic examination of urine samples, combined with highly sensitive and specific molecular approaches. Altogether, our goal on better control and prevention of urinary schistosomiasis may not be achievable, unless by a global collaboration to accurately reveal the parasite epidemiology in endemic territories.

**Abbreviations**

UGS: Urogenital schistosomiasis; BCE: Before common era; WHO: World Health Organization; PCR: Polymerase chain reaction; FUS: Female urinary schistosomiasis; MeSH: Medical subject heading; CI: Confidence interval; CMA: Comprehensive meta-analysis; HIV-1: Human immunodeficiency virus-1; MDA: Mass drug administration.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s41182-022-00402-x.

Additional file 1. PRISMA checklist employed for the present systematic review.

Additional file 2. Forest plot of the FUS prevalence obtained from published literature during 2016–2020.

Additional file 3. Quality assessment analysis of the included papers using Newcastle–Ottawa scale.

**Acknowledgements**

Not applicable.
Authors' contributions

MS, SK and AA conceived the study protocol; SK, HM and SB performed the systematic search; EJ and SB extracted the required information from included papers; SB, EJ and DA performed the meta-analytical approach; NN, MF, EG and TN wrote the manuscript draft; MS and AA critically revised the manuscript. All authors have read and approved the manuscript.

Funding

The authors did not receive support from any organization for the submitted work.

Availability of data and materials

The dataset(s) supporting the conclusions of this article is(are) included within the article (and its additional files).

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

1 Zoonotic Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran. 2 Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. 3 Department of Medical Parasitology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran. 4 Department of Parasitology and Mycology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. 5 Clinical Research Development Center, “The Persian Gulf Martyrs” Hospital of Bushehr University of Medical Sciences, Bushehr, Iran. 6 Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran. 7 Department of Parasitology, Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran. 8 School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran. 9 Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 10 Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Received: 7 June 2021 Accepted: 12 January 2022

Published online: 29 January 2022

References

1. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. The Lancet. 2014;383(9936):2253–64.
2. Ross AG, Chau TN, Inobaya MT, Olveda RM, Li Y, Harn DA. A new global strategy for the elimination of schistosomiasis. Elsevier, 2017.
3. Frahm S, Ansizuzzaman A, Prodjinjtho UF, Véjigant N, Verschoor A, Prazeres da Costa C. A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing. PLoS Negl Trop Dis. 2019;13(1):e0006590.
4. Ansizuzzaman, Tsui N. Schistosomiasis and hookworm infection in humans: disease burden, pathobiology and anthelmintic vaccines. Parasitol Int. 2020;10201.
5. Rollinson D. A wake up call for urinary schistosomiasis: reconsil- ing research effort with public health importance. Parasitology. 2009;136(12):1593–610.
6. Siddiqui AA, Siddiqui SZ. Sm-p80-based schistosomiasis vaccine: prepa- ration for human clinical trials. Trends Parasitol. 2017;33(3):194–201.
7. Chabasse D, Bertrand G, Leroux J, Gauthey N, Hocquet P. Developmental bilharziasis caused by Schistosoma mansoni discovered 37 years after infestation. Bulletin de la Société de pathologie exotique et de ses filiales. 1985;78(5):643–7.
8. Warren KS, Mahmoud AA, Cummings P, Murphy DJ, Houser HB. Chistosomiasis mansoni in Yemeni in California: duration of infection, presence of disease, therapeutic management. Am J Trop Med Hyg. 1974;23(5):902–9.
9. Ansizuzzaman SF, Prodjinjtho UF, Bhattacharjee S, Verschoor A, da Costa CP. Host-specific serum factors control the development and survival of Schistosoma mansoni. Front Immunol. 2021;12.
10. Ansari N. Epidemiology and control of schistosomiasis (bilharziasis). Switzerland: CABI; 1973.
11. Grevelding CG, Langner S, Distous C. Kinases: molecular stage directors for schistosome development and differentiation. Trends Parasitol. 2018;34(3):246–60.
12. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou X-N. Schistosomiasis. Nat Rev. 2018;4(1):13.
13. Ritter M, Gross Q, Kays S, Ruland J, Nimmerjahn F, Saijo S, et al. Schisto- somas mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. Proc Natl Acad Sci. 2010;107(47):20459–64.
14. Kameh D, Smith A, Brock-M, Ndubusi B, Masoed S. Female genital schistosomiasis: case report and review of the literature. J Sex Med. 2004;97(5):525–8.
15. Kayun S, Lampiao F, Makaula P, Aziwelio L, LacOURCE EJ, Reinhard-Rupp J, et al. A systematic review with epidemiological update of male geni- tal schistosomiasis (MGS): a call for integrated case management across the health system in sub-Saharan Africa. Parasite Epidemiol Control. 2019;4:e00077.
16. Santos LL, Joura S, Gouveia MJ, Bernardo C, Lopes C, Rinaldi G, et al. Urogenital schistosomiasis—history, pathogenesis, and bladder cancer. J Clin Med. 2021;10(2):205.
17. Organization WH. The control of schistosomiasis: second report of the WHO Expert Committee [meeting held in Geneva from 8–15 November 1991]. World Health Organization, 1993.
18. Organization WH. Preventive chemotherapy in human helminthiasis. Coordinated use of anthelmintic drugs in control interventions: a manual for health professionals and programme managers. World Health Organization; 2006.
19. Colley DG, Binder S, Campbell C, King CH, Tchuenté L-AT, Noran shrink, et al. A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of Schistosoma mansoni. Am J Trop Med Hygiene. 2013;88(3):426–32.
20. Mott K, Dixon H. Collaborative study on antigens for immunodiagnosis of schistosomiasis. Bull World Health Organ. 1982;60(5):729.
21. Ajibola O, Gulumbie BH, Eze AA, Obihakin E. Tools for detection of schistosomiasis in resource limited settings. Med Sci. 2018;6(2):39.
22. Kjetland EF, Ten Hove RJ, Gomo E, Midzi N, Gwanzura L, Mason P, et al. Schistosomiasis PCR in vaginal lavage as an indicator of genital Schisto- somas haematobium infection in rural Zimbabwean women. Am J Trop Med Hyg. 2009;81(6):1505–5.
23. Barsoum RS. Urinary schistosomiasis. J Adv Res. 2013;4(5):453–9.
24. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
25. Anvari D, Pourmalek N, Rezaei S, Fotovati A, Hosseini SA, Daryani A, et al. The global status and genetic characterization of hydatidosis in camels (Camelus dromedarius): a systematic literature review with meta-analy- sis based on published papers. Parasitology. 2021;1–54.
26. Ghasemi E, Shariatzadeh SA, Shamsinia S, Anvari D, Shariatzadeh SA, et al. Filarial worms: a systematic review and meta-analysis of diversity in animals from Iran with emphasis on human cases. Parasitol- ogy. 2020;147(9):909–21.
27. Javanmardi E, Majidiani H, Shariatzadeh SA, Anvari D, Bahadory S, Shariatzadeh SA, et al. Prevalence of fasciolosis in livestock and humans: a systematic review and meta-analysis. Comp Immunol Microbiol Infect Dis. 2019;65:116–23.
28. Khademvatan S, Majidiani H, Khalkhali H, Taghpour A, Asadi N, Yousufi E. Prevalence of fascioliasis in livestock and humans: a systematic review and meta-analysis in Iran. Comp Immunol Microbiol Infect Dis. 2019;65:116–28.
29. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–29.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research ed). 2003;327(7414):557–60.
31. Egger M, Smith GD. Misleading meta-analysis. BMJ (Clinical Research ed). 1995;311(7007):753–4.
32. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–63.
33. Abah AE, Onoha H, Nduka FO, Arene FO. Current status of urinary schistosomiasis and some pre-disposing factors in Emellego Community, Rivers State, Nigeria. Acta Parasitol Global. 2016;7(2):74–80.
34. Abdukareem BO, Habeeb KO, Kazeem A, Adam AO, Samuel UU. Urogenital schistosomiasis among school children and the associated risk factors in selected rural communities of Kwarara State, Nigeria. J Trop Med. 2018;2018:693198.
35. Abubakar S, Zakariya M, Ahmad MK, Abdullahi MK, Yunusa I. CO-occurrence of urinary schistosomiasis and some pre-disposing factors among school age children in Ikota, Southwestern Nigeria. Braz J Biol Sci. 2019;63(13):391–9.
36. DA Adamu AM, Akefe OI, Alimi YA, Adikwu AA, Idoko SI, Olowo OA, Oke AA, Yikawe SS, Bello SG, Lamai RS, Kolo RL. Epidemiology of urinary schistosomiasis infection among school children in an Endemic Nigerian Community. Korean J Parasitol. 2018;56(6):577–81.
37. Aderibigbe SA, Okpareke O, Adaramola SO. Diagnosis of urinary schistosomiasis and associated determinant factors among senior high school students in the Urgas-Ma and Sahana Local Government Areas of Katsina State, Nigeria. Infect Dis Poverty. 2016;5(1):69.
38. Atefi A, Ahmed AA, Suleiman Y, Pengsakul T. Epidemiology of schistosomiasis among villagers of the New Halfa Agricultural Scheme, Sudan. Iran J Parasitol. 2016;11(1):110–5.
39. Ahmed A, Gidado SM. Prevalence of schistosomiasis among schoolchildren in Iyataya and Faduma communities, Rimi local government area, Katsina state. Katsina J Natl Appl Sci. 2019;7(1):3–10.
40. Akinyeye JOFM, Afolabi OJ, Adesina FP. Prevalence of urinary schistosomiasis among secondary school students in Ifedore Local Government, Ondo State Nigeria. Int J Trop Dis Health. 2018;33(1):1–7.
41. Akpin SS, Dike PC, Mbah M. The prevalence of urinary schistosomiasis among schoolchildren in Nikara and Edor communities in Ikom Local Government Area of Cross River State, Nigeria. Pyrex J Med Sci. 2017;4(1):1–6.
42. Akpin SS, Dike PC, Mbah M. The prevalence of urinary schistosomiasis among schoolchildren in Nikara and Edor communities in Ikom Local Government Area, Ondo State Nigeria. Int J Trop Dis. 2018;1(1):1–6.
43. Alabi P, Oladejo SO, Odaibo AB. Prevalence and intensity of urinary schistosomiasis in Ogun state, Southwest, Nigeria. J Public Health Epidemiol. 2018;10(1):413–7.
44. Amoo KJ, Amoo OA, Adeboyega TT. Prevalence of Urinary Tract Infection (UTI) and concomitant urinary Schistosomiasis among Primary School Children in Remo North Local Government, Ogun State, Nigeria. IOSR J Dent Med Sci. 2017;16(11):68–73.
45. Anchang-Kimbi JK, Elad DM, Sotoing GT, Achidi EA. Coinfection with Schistosoma haematobium and Plasmodium falciparum and Anaemia severity among pregnant women in Munyenge, Mount Cameroon Area: a cross-sectional study. J Parasitol Res. 2017;2017:6713465.
46. Anorue CO, Nwoke BEB, Ikaga CN. The incidence of urinary Schistosomiasis in Chaukwo Local Government Area of Ebonyi. Asian J Biomed Pharm Sci. 2017;7(6):1–5.
47. Arhin-Wiredu K, Kum K, Quarseille SS, Tawiah PA, Oduro EA, Hatorvi C, et al. Prevalence and associated factors of urinary Schistosomiasis among basic school children in the Akwesanzas District, Ghana. Asian J Med Health. 2019;1–10.
48. Abiodun DJ, Bassey SA, Younan T, Sam-Wobu SO, Abiodun OB, Ugwunyik IK. Analysis of Schistosomiasis and soil-transmitted helminths mixed infections among pupils in Enugu State, Nigeria: implications for control. Infect Dis Health. 2019;24(2):98–106.
49. Atefi A, Ahmed AA, Suleiman Y, Pengsakul T. Prevalence and intensity of urinary schistosomiasis among school age children in Ikota, Southwestern Nigeria. Braz J Biol Sci. 2019;63(13):391–9.
50. Atefi A, Sharimam YZ, Haiqizah MTF, Olusi TA. Will Nigerians win the war against urinary Schistosomiasis? Prevalence, intensity, risk factors and knowledge assessment among some rural communities in Southwestern Nigeria. Pathogens. 2020;9(2):128.
51. Atefi A, Ipinlaye SJ. Prevalence and intensity of urinary schistosomiasis among school children in Ikota, Southwestern Nigeria. J Res Publ. 2018;13(1):12.
52. Atefi A, Ipinlaye SJ. Urogenital schistosomiasis and associated determinant factors among senior high school students in the Urgas-Ma and Sahana Local Government Areas of Katsina State, Nigeria. Infect Dis Poverty. 2016;5(1):69.
53. Anrue CO, Nwoke BEB, Ikaga CN. The incidence of urinary Schistosomiasis in Chaukwo Local Government Area of Ebonyi. Asian J Biomed Pharm Sci. 2017;7(6):1–5.
54. Andrews RM, Dos Santos JS, Gathua S, Ching’o M, des Portos AS, Dibo AD, et al. Schistosoma mansoni infection among primary school children in three rural communities of Kano State, Nigeria. Niger Ann Pure Appl Sci. 2018;1(1):7–13.
70. Ebong NE, Abah AE. Preliminary studies on urinary Schistosomiasis in selected communities in Itu Local Government Area, Akwa Ibom State, Nigeria. J Pharm Biocatal. 2018;13(6):55–61.
71. Ekanem EE, Akpan FM, Eyong NE. Urinary schistosomiasis in school children of a southern Nigerian community 8 years after the provision of potable water. Niger Postgrad Med J. 2017;24(4):201–4.
72. Elhusen S. Surveillance of Schistosoma species among population of Greater Wad Medani Locality, Gezira State, Sudan (2016). University of Gezira. 2016.
73. Etem JE, Odekunmoro OO, Nnachi AU, Ikhe I, Nkwudja JO. Variability of urine parameters in children infected with Schistosoma haematobium in Ukawu community, Onicha Local Government Area, Ebonyi State, Nigeria. Afr J Infect Dis. 2017;11(2):10–6.
74. Elsiddig HA. Prevalence of urinary schistosomiasis among schoolchildren in White Nile State, Sudan. Afr Educ Res J. 2019;7(1):29–32.
75. Emmanuel OI, Agbo OE, Uche AJ, Odeh UP, Agogo IM. Comparative evaluation of the prevalence of urinary schistosomiasis in two contrasting communities in Benue State, Nigeria. Int J Infect Dis Therapy. 2017;2(3):48–52.
76. Fokuo Ofori M, Opoku Peprah B, Adukpo S, Kakra Dickson E, Anim-Kofi A. Prevalence of urinary Schistosomiasis among selected communities in Itu Local Government Area, Akwa Ibom State, Nigeria. J Microbiol Biotechnol. 2020;5(2):69.
77. Galappaththi-Arachchige HN, Amlie Hegertun IE, Holmen S, Qvigstad E, Kleppa E, Sebitloane M, et al. Association of urogenital symptoms with Schistosoma haematobium infection in women: a cross-sectional study in rural Africa. Int J Environ Res Public Health. 2016;13(11).
78. Galappaththi-Arachchige HN, Holmen S, Koukounari A, Kleppa E, Pillay P, Sebitloane M, et al. Evaluating diagnostic indicators of urogenital Schistosoma haematobium infection in young women: a cross-sectional study in rural South Africa. PLoS ONE. 2018;13(2):e0191459.
79. Ganau AM, Mohammed K, Spencer TH, Nataala S, Ashcroft O, Nuhu A, et al. Prevalence of urinary Schistosomiasis among primary school children in Kwakwalawa Area, Sokoto State, North-Western Nigeria. Asian J Res Med Pharm Sci. 2018;3(1):1–10.
80. Ganau AM, Mohammed K, Halalay S, Awadalla A, Balla S. Prevalence, risk factors and effect of urinary Schistosomiasis on academic performance of school children age 6–15 years in Asalaya Local, White Nile, Sudan. 2017. J Adv Med Res. 2018;28(8):1–7.
81. Mong K, Chikodi S, Ihemamna CA. Current prevalence status of urinary Schistosomiasis among children in Lokpanta Community, Abia State, Nigeria. Galore Int J Health Sci Res. 2016;1(1):35–40.
82. Mogulemeke OA, Eleng IE, Atanda OS, Oyeyemi OT. Renal related disorders in concomitant Schistosoma haematobium-Plasmodium falciparum infection among children in a rural community of Nigeria. J Infect Public Health. 2016;9(2):136–42.
83. Mov B, Changadeya W, Chionto S, Siiaka D. Urinary schistosomiasis among preschool children in Malangachanzi, Nkhokotata District, Malawi: prevalence and risk factors. Malawi Med J. 2016;28(1):10–4.
84. Morenikeji OA, Eleng IE, Atanda OS, Oyeyemi OT. Renal related disorders in concomitant Schistosoma haematobium-Plasmodium falciparum infection among children in a rural community of Nigeria. J Infect Public Health. 2016;9(2):136–42.
85. Mooy VB, Changadeya W, Chionto S, Siiaka D. Urinary schistosomiasis among preschool children in Malangachanzi, Nkhokotata District, Malawi: prevalence and risk factors. Malawi Med J. 2016;28(1):10–4.
86. Mubara M, Ali GA, Hajissa K. Prevalence and intensity of urinary Schistosomiasis among selected people in Tulus Area, South Darfur State, Sudan. 2020:2–8.
87. Nnemekwe J, Hassan J, Opulauwa SA, Adadam T, Spencer TH, Aschroft CH, et al. Prevalence of urinary Schistosomiasis among school-age children in Kashinaya and Sabyi in Alery Local Government Area, Kebbi State, Nigeria. South Asian J Parasitol. 2018;11(1):1–8.
88. Ngwamah JS, Naphtali RS. Prevalence and intensity of urinary Schistosomiasis among school-going children in the Ndumo area, uMhanyakude district, South Africa. South Afr J Infect Dis. 2017;32(2):67–72.
89. Kaligova A, Changoma MJ, Spajdelova J, Jakubcova D, Birovka K. Urinary schistosomiasis in patients of rural medical health centers in Kwaile county, Kenya. Helminthologia. 2020;57(1):19–27.
90. Kayun S, Peeling R, Makaula P. Prevalence and distribution of Schistosoma haematobium infection among school children living in southwestern shores of Lake Malawi. Malawi Med J. 2017;29(1):16–23.
91. Kenneth IE, Iohan IM, Godwin NO. Bacteriuria and urinary Schistosomiasis among individuals in Ewevan community Akoko—Edo, Edo State, Nigeria. Am J Microbiol Biotechnol. 2017;4(3):27–30.
92. Maki A, Ali GA, Hajissa K. Prevalence and intensity of urinary Schistosomiasis among selected people in Tulus Area, South Darfur State, Sudan. 2020:2–8.
93. Mohammed K, Mubara M, Ali GA, Hajissa K. Prevalence and intensity of urinary Schistosomiasis among school-age children in Kashinaya and Sabyi in Alery Local Government Area, Kebbi State, Nigeria. South Asian J Parasitol. 2018;11(1):1–8.
94. Mohammed K, Suwabba M, Spencer T, Nataala S, Ashcroft O, Nuhu A, et al. Prevalence of urinary Schistosomiasis among primary school children in Kwakwalawa Area, Sokoto State, North-Western Nigeria. Asian J Res Med Pharm Sci. 2018;3(1):1–10.
95. Mohammed K, Suwabba M, Spencer T, Nataala S, Ashcroft O, Nuhu A, et al. Prevalence of urinary Schistosomiasis among primary school children in Kwakwalawa Area, Sokoto State, North-Western Nigeria. Asian J Res Med Pharm Sci. 2018;3(1):1–10.
96. Mohammed MM, Halalay S, Awadalla A, Balla S. Prevalence, risk factors and effect of urinary Schistosomiasis on academic performance of school children age 6–15 years in Asalaya Local, White Nile, Sudan. 2017. J Adv Med Res. 2018;28(8):1–7.
97. Mombo-Ngoma G, Nonpehejedj J, Basra A, Mackanga JR, Zoleko RM, Zinsou J, et al. Urogenital schistosomiasis during pregnancy is associated with low birth weight delivery: analysis of a prospective cohort of pregnant women and their offspring in Gabon. Int J Parasitol. 2017;47(1):69–74.
98. Mong K, Chikodi S, Ihemamna CA. Current prevalence status of urinary Schistosomiasis among children in Lokpanta Community, Abia State, Nigeria. Galore Int J Health Sci Res. 2016;1(1):35–40.
99. Morenikeji OA, Eleng IE, Atanda OS, Oyeyemi OT. Renal related disorders in concomitant Schistosoma haematobium-Plasmodium falciparum infection among children in a rural community of Nigeria. J Infect Public Health. 2016;9(2):136–42.
100. Moyo VB, Changadeya W, Chionto S, Siiaka D. Urinary schistosomiasis among preschool children in Malangachanzi, Nkhokotata District, Malawi: prevalence and risk factors. Malawi Med J. 2016;28(1):10–4.
101. Mubara M, Ali GA, Hajissa K. Prevalence and intensity of urinary Schistosomiasis among school-going children in the Ndumo area, uMhanyakude district, South Africa. South Afr J Infect Dis. 2017;32(2):67–72.
102. Kaligova A, Changoma MJ, Spajdelova J, Jakubcova D, Birovka K. Urinary schistosomiasis in patients of rural medical health centers in Kwaile county, Kenya. Helminthologia. 2020;57(1):19–27.
Oluwatoyin AH, Ajide P, Awobode HO, Osundiran AJ, Onile OS, Adebayo AS, et al. Prevalence of urinary tract pathology in some communities in Oyo state, Nigeria. J Public Health Epidemiol. 2016;2(3):38–44.

Oluwokanmi OA, Adeniran AA, Mogaji HO, Olatunbosun OA, Bankole RA, et al. Prevalence and intensity of urinary schistosomiasis infection and anaemia in children in Accra. Ghana Trop Dis Travel Med Vaccines. 2018;4:3.

Oluwayi AO, K十三rd O, Adeniyi AO, Adekunle OA, Adebiyi OA, et al. Prevalence and intensity of urinary Schistosoma haematobium infection: prevalence and morbidity indicators in communities around Wasai Dam, Minjibir, Kano State, Northern Nigeria. Int J Trop Dis Health. 2016;17(2):1–8.

Obisike VO, Okwu N, Amodu B, et al. Prevalence and Intensity of urinary schistosomiasis infection among primary school children in Dawakin kudu local government area, Kano state, Nigeria. J Trop Pediatr Child Health. 2019;35(3):222–9.

Olawoju FO, Adebayo AO, Oparinde KO, Aliyu I, et al. Prevalence of urinary tract infection among primary school children in Oyo state, Nigeria. Trop J Pediatr. 2019;25(1):21–6.

Oluwole AS, Adeniran AA, Mogaji HO, Olabinke DB, Abe EM, et al. Co-infection of schistosomiasis, malaria, HBV and HIV among adults living in Eggu Community, Ogun State, Nigeria. Niger J Parasitol. 2020;41(1):82–6.

Oluwatoyin AH, Olukemi OD, Omolara OA, Adetola AT. Prevalence of Schistosoma and other parasites among female residents of some communities in Oyo state, Nigeria. J Public Health Epidemiol. 2016;2(3):38–44.

Oluwokanmi OA, Adeniran AA, Mogaji HO, Olatunbosun OA, Bankole RA, et al. Prevalence and intensity of urinary schistosomiasis infection and anaemia in children in Accra. Ghana Trop Dis Travel Med Vaccines. 2018;4:3.

Oluwatoyin AH, Ajide P, Awobode HO, Osundiran AJ, Onile OS, Adebayo AS, et al. Prevalence of urinary tract pathology in some communities in Oyo state, Nigeria. J Public Health Epidemiol. 2016;2(3):38–44.

Oluwokanmi OA, Adeniran AA, Mogaji HO, Olatunbosun OA, Bankole RA, et al. Prevalence and intensity of urinary schistosomiasis infection and anaemia in children in Accra. Ghana Trop Dis Travel Med Vaccines. 2018;4:3.
152. Khalaf I, Shokeir A, Shalaby M. Urologic complications of genitourinary schistosomiasis. World J Urol. 2012;30(1):31–8.

153. Schwartz D. Helminths in the induction of cancer II. Schistosoma haematobium and bladder cancer. Trop Geogr Med. 1981;33(1):1–7.

154. Figueiredo JC, Richter J, Borja N, Balaca A, Costa S, Belo S, et al. Prostate adenocarcinoma associated with prostatic infection due to Schistosoma haematobium. Case report and systematic review. Parasitol Res. 2015;114(2):351–8.

155. Richardson ML, Fu C-L, Pennington LF, Honeycutt JD, Odegaard JL, Hsieh Y-J, et al. A new mouse model for female genital schistosomiasis. PLoS Negl Trop Dis. 2014;8(5):e2825.

156. Talat M, Watts S, Mekheimar S, Ali HF, Hamed H. The social context of reproductive health in an Egyptian hamlet: a pilot study to identify female genital schistosomiasis. Soc Sci Med. 2004;58(3):515–24.

157. Sturt A, Webb E, Francis S, Hayes R, Bustinduy A. Beyond the barrier: female genital schistosomiasis as a potential risk factor for HIV-1 acquisition. Acta Trop. 2020;205:24.

158. Patel P, Rose CE, Kjeldsen EF, Downs JA, Mbabazi PS, Sabin K, et al. Association of schistosomiasis and HIV infections: a systematic review and meta-analysis. Int J Infect Dis. 2020.

159. Ribeiro AR, Lus C, Fernandes R, Botelho MC. Schistosomiasis and infertility: what do we know? Trends Parasitol. 2019;35(12):964–71.

160. Chadeka EA, Naji S, Sunahara T, Cheruyoit NB, Bahati F, Ozeki Y, et al. Spatial distribution and risk factors of Schistosoma haematobium and hookworm infections among schoolchildren in Kwale, Kenya. PLoS Negl Trop Dis. 2017;11(9):e0005872.

161. Corstjens PL, Hoekstra PT, Claudia J, van Dam GJ. Utilizing the ultrasensitive Schistosoma up-converting phosphor lateral flow circulating anodic antigen (UCP-LF CAA) assay for sample pooling-strategies. Infect Dis Poverty. 2017;6(1):1–13.

162. Gray DJ, Ross AG, Li Y-S, McManus DP. Diagnosis and management of schistosomiasis. BMJ. 2011;342:d2651.

163. Weerakoon KG, Gobert GN, Cai P, McManus DP. Advances in the diagnosis of human schistosomiasis. Clin Microbiol Rev. 2015;28(4):939–67.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.